Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy

Sponsor
University Hospital Tuebingen
Study ID
NCT07337876
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dose escalated radiotherapy using a 1.5 T MR-Linac — RADIATION
    Dose escalated radiotherapy using a 1.5 T MR-Linac is given to the primary tumor and affected lymph nodes in an online adaptive manner

Study Details

This study is testing whether radiation delivered with MRI guidance using a so-called MR-linac in distal rectal cancer can result in a high rate of organ preservation. Patients will receive radiotherapy together with standard chemotherapy.

Key Dates

First listed
Jan 13, 2026
Start date
Jan 7, 2026
Status verified
Feb 2026
Primary completion
Jan 31, 2029
Completion
Jan 31, 2029

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MR guided dose escalated radiotherapy
    A dose of 65 Gy is delivered to the primary tumor and affected lymph nodes.

Primary Outcome Measure

Two year TME-free survival [ Time Frame: Two years from the start of radiotherapy ]

Central Contacts

Find similar trials

Nationwide
Colorectal cancer trialsOncology trialsGI oncology trials

Related Studies